Opinion

Video

Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing

Key Takeaways

  • Strategic sequencing of bispecific antibodies and CAR T-cell therapy is crucial for optimizing outcomes in RRMM treatment.
  • Operational challenges include coordinating multidisciplinary teams, managing toxicities, and ensuring timely access to therapies.
SHOW MORE

Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.

Video content above is prompted by the following

  • How has this impacted sequencing of bispecific antibodies and CAR T-cell therapy for patients at your institution?
  • What operational challenges do institutions often face in terms of the use of bispecific antibodies in patients with RRMM, and how has your institution addressed these challenges?
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.